Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103289287> ?p ?o ?g. }
- W2103289287 endingPage "2266" @default.
- W2103289287 startingPage "2259" @default.
- W2103289287 abstract "Purpose The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Patients and Methods Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). Results With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide- (41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months; 60% completely resolved within a median of 5.7 months. Conclusion VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent–based treatment until relapse." @default.
- W2103289287 created "2016-06-24" @default.
- W2103289287 creator A5001068881 @default.
- W2103289287 creator A5016199509 @default.
- W2103289287 creator A5016322565 @default.
- W2103289287 creator A5017461150 @default.
- W2103289287 creator A5019718106 @default.
- W2103289287 creator A5020989412 @default.
- W2103289287 creator A5029035458 @default.
- W2103289287 creator A5029159537 @default.
- W2103289287 creator A5030524608 @default.
- W2103289287 creator A5033573338 @default.
- W2103289287 creator A5037979752 @default.
- W2103289287 creator A5043526996 @default.
- W2103289287 creator A5045814742 @default.
- W2103289287 creator A5046364210 @default.
- W2103289287 creator A5049970120 @default.
- W2103289287 creator A5054311119 @default.
- W2103289287 creator A5058355502 @default.
- W2103289287 creator A5059967673 @default.
- W2103289287 creator A5065901710 @default.
- W2103289287 creator A5082309872 @default.
- W2103289287 date "2010-05-01" @default.
- W2103289287 modified "2023-10-18" @default.
- W2103289287 title "Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial" @default.
- W2103289287 cites W1978377409 @default.
- W2103289287 cites W1983597383 @default.
- W2103289287 cites W1989740966 @default.
- W2103289287 cites W2012843756 @default.
- W2103289287 cites W2066295909 @default.
- W2103289287 cites W2066800926 @default.
- W2103289287 cites W2074340459 @default.
- W2103289287 cites W2082741854 @default.
- W2103289287 cites W2088540908 @default.
- W2103289287 cites W2089294472 @default.
- W2103289287 cites W2096207943 @default.
- W2103289287 cites W2101576302 @default.
- W2103289287 cites W2104879150 @default.
- W2103289287 cites W2110466835 @default.
- W2103289287 cites W2119584679 @default.
- W2103289287 cites W2120474651 @default.
- W2103289287 cites W2136373453 @default.
- W2103289287 cites W2137061476 @default.
- W2103289287 cites W2156748957 @default.
- W2103289287 cites W2172122039 @default.
- W2103289287 cites W2242783700 @default.
- W2103289287 cites W2550787877 @default.
- W2103289287 cites W2555603866 @default.
- W2103289287 cites W2559045020 @default.
- W2103289287 cites W2571061086 @default.
- W2103289287 cites W2588287144 @default.
- W2103289287 cites W2589054503 @default.
- W2103289287 cites W2592909439 @default.
- W2103289287 doi "https://doi.org/10.1200/jco.2009.26.0638" @default.
- W2103289287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20368561" @default.
- W2103289287 hasPublicationYear "2010" @default.
- W2103289287 type Work @default.
- W2103289287 sameAs 2103289287 @default.
- W2103289287 citedByCount "389" @default.
- W2103289287 countsByYear W21032892872012 @default.
- W2103289287 countsByYear W21032892872013 @default.
- W2103289287 countsByYear W21032892872014 @default.
- W2103289287 countsByYear W21032892872015 @default.
- W2103289287 countsByYear W21032892872016 @default.
- W2103289287 countsByYear W21032892872017 @default.
- W2103289287 countsByYear W21032892872018 @default.
- W2103289287 countsByYear W21032892872019 @default.
- W2103289287 countsByYear W21032892872020 @default.
- W2103289287 countsByYear W21032892872021 @default.
- W2103289287 countsByYear W21032892872022 @default.
- W2103289287 countsByYear W21032892872023 @default.
- W2103289287 crossrefType "journal-article" @default.
- W2103289287 hasAuthorship W2103289287A5001068881 @default.
- W2103289287 hasAuthorship W2103289287A5016199509 @default.
- W2103289287 hasAuthorship W2103289287A5016322565 @default.
- W2103289287 hasAuthorship W2103289287A5017461150 @default.
- W2103289287 hasAuthorship W2103289287A5019718106 @default.
- W2103289287 hasAuthorship W2103289287A5020989412 @default.
- W2103289287 hasAuthorship W2103289287A5029035458 @default.
- W2103289287 hasAuthorship W2103289287A5029159537 @default.
- W2103289287 hasAuthorship W2103289287A5030524608 @default.
- W2103289287 hasAuthorship W2103289287A5033573338 @default.
- W2103289287 hasAuthorship W2103289287A5037979752 @default.
- W2103289287 hasAuthorship W2103289287A5043526996 @default.
- W2103289287 hasAuthorship W2103289287A5045814742 @default.
- W2103289287 hasAuthorship W2103289287A5046364210 @default.
- W2103289287 hasAuthorship W2103289287A5049970120 @default.
- W2103289287 hasAuthorship W2103289287A5054311119 @default.
- W2103289287 hasAuthorship W2103289287A5058355502 @default.
- W2103289287 hasAuthorship W2103289287A5059967673 @default.
- W2103289287 hasAuthorship W2103289287A5065901710 @default.
- W2103289287 hasAuthorship W2103289287A5082309872 @default.
- W2103289287 hasBestOaLocation W21032892871 @default.
- W2103289287 hasConcept C126322002 @default.
- W2103289287 hasConcept C141071460 @default.
- W2103289287 hasConcept C197934379 @default.
- W2103289287 hasConcept C207103383 @default.
- W2103289287 hasConcept C2776063141 @default.